For adults with neuromyelitis optica spectrum disorder (NMOSD), rituximab and Uplizna (inebilizumab) work equally well to prevent disease relapses, but Uplizna appears to be safer because it causes fewer infusion-related side effects. Those are the main findings of a real-world study analyzing data from more than 250 NMOSD…